Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2020 · 10-Q
Revenue$98.91M$98.91M+572.9% vs Q3 2019 Net Income$8.79M$8.79MN/M vs Q3 2019 EPS Diluted$0.23$0.23N/M vs Q3 2019 Operating Income$13,951,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$42,532,000N/M Margins · derivedOperating margin14.1%+258.3 pt vs Q3 2019
Net margin8.9%+244.2 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 4, 2020 · 35 d after period end